Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1946 4
1948 1
1949 3
1950 8
1951 8
1952 5
1953 4
1954 5
1955 10
1956 5
1957 5
1958 14
1959 8
1960 9
1961 7
1962 31
1963 65
1964 71
1965 48
1966 83
1967 97
1968 132
1969 156
1970 193
1971 194
1972 205
1973 153
1974 173
1975 153
1976 149
1977 110
1978 102
1979 117
1980 106
1981 129
1982 114
1983 165
1984 195
1985 286
1986 243
1987 244
1988 183
1989 171
1990 136
1991 97
1992 98
1993 102
1994 111
1995 114
1996 143
1997 155
1998 218
1999 286
2000 375
2001 543
2002 593
2003 585
2004 721
2005 933
2006 1000
2007 1110
2008 1199
2009 1214
2010 1324
2011 1486
2012 1684
2013 1851
2014 2013
2015 1999
2016 1867
2017 1904
2018 1903
2019 1976
2020 2046
2021 1923
2022 1303
2023 478
2024 382

Text availability

Article attribute

Article type

Publication date

Search Results

33,808 results

Results by year

Filters applied: . Clear all
Page 1
Zuranolone for the Treatment of Postpartum Depression.
Deligiannidis KM, Meltzer-Brody S, Maximos B, Peeper EQ, Freeman M, Lasser R, Bullock A, Kotecha M, Li S, Forrestal F, Rana N, Garcia M, Leclair B, Doherty J. Deligiannidis KM, et al. Am J Psychiatry. 2023 Sep 1;180(9):668-675. doi: 10.1176/appi.ajp.20220785. Epub 2023 Jul 26. Am J Psychiatry. 2023. PMID: 37491938 Clinical Trial.
Acute graft-versus-host disease.
Malard F, Holler E, Sandmaier BM, Huang H, Mohty M. Malard F, et al. Nat Rev Dis Primers. 2023 Jun 8;9(1):27. doi: 10.1038/s41572-023-00438-1. Nat Rev Dis Primers. 2023. PMID: 37291149 Review.
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study.
Passaro A, Wang J, Wang Y, Lee SH, Melosky B, Shih JY, Wang J, Azuma K, Juan-Vidal O, Cobo M, Felip E, Girard N, Cortot AB, Califano R, Cappuzzo F, Owen S, Popat S, Tan JL, Salinas J, Tomasini P, Gentzler RD, William WN Jr, Reckamp KL, Takahashi T, Ganguly S, Kowalski DM, Bearz A, MacKean M, Barala P, Bourla AB, Girvin A, Greger J, Millington D, Withelder M, Xie J, Sun T, Shah S, Diorio B, Knoblauch RE, Bauml JM, Campelo RG, Cho BC; MARIPOSA-2 Investigators. Passaro A, et al. Ann Oncol. 2024 Jan;35(1):77-90. doi: 10.1016/j.annonc.2023.10.117. Epub 2023 Oct 23. Ann Oncol. 2024. PMID: 37879444 Free article. Clinical Trial.
Variant STAT4 and Response to Ruxolitinib in an Autoinflammatory Syndrome.
Baghdassarian H, Blackstone SA, Clay OS, Philips R, Matthiasardottir B, Nehrebecky M, Hua VK, McVicar R, Liu Y, Tucker SM, Randazzo D, Deuitch N, Rosenzweig S, Mark A, Sasik R, Fisch KM, Pimpale Chavan P, Eren E, Watts NR, Ma CA, Gadina M, Schwartz DM, Sanyal A, Werner G, Murdock DR, Horita N, Chowdhury S, Dimmock D, Jepsen K, Remmers EF, Goldbach-Mansky R, Gahl WA, O'Shea JJ, Milner JD, Lewis NE, Chang J, Kastner DL, Torok K, Oda H, Putnam CD, Broderick L. Baghdassarian H, et al. N Engl J Med. 2023 Jun 15;388(24):2241-2252. doi: 10.1056/NEJMoa2202318. Epub 2023 May 31. N Engl J Med. 2023. PMID: 37256972 Free PMC article.
Zuranolone: First Approval.
Heo YA. Heo YA. Drugs. 2023 Nov;83(16):1559-1567. doi: 10.1007/s40265-023-01953-x. Drugs. 2023. PMID: 37882942 Review.
Palovarotene.
[No authors listed] [No authors listed] Am J Health Syst Pharm. 2023 Dec 5;80(24):1763-1767. doi: 10.1093/ajhp/zxad229. Am J Health Syst Pharm. 2023. PMID: 37796111 No abstract available.
ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma.
Zinzani PL, Mayer J, Flowers CR, Bijou F, De Oliveira AC, Song Y, Zhang Q, Merli M, Bouabdallah K, Ganly P, Zhang H, Johnson R, Martín García-Sancho A, Provencio Pulla M, Trněný M, Yuen S, Tilly H, Kingsley E, Tumyan G, Assouline SE, Auer R, Ivanova E, Kim P, Huang S, Delarue R, Trotman J. Zinzani PL, et al. J Clin Oncol. 2023 Nov 20;41(33):5107-5117. doi: 10.1200/JCO.23.00775. Epub 2023 Jul 28. J Clin Oncol. 2023. PMID: 37506346 Clinical Trial.
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.
Pant S, Schuler M, Iyer G, Witt O, Doi T, Qin S, Tabernero J, Reardon DA, Massard C, Minchom A, Lugowska I, Carranza O, Arnold D, Gutierrez M, Winter H, Stuyckens K, Crow L, Najmi S, Hammond C, Thomas S, Santiago-Walker A, Triantos S, Sweiti H, Loriot Y; RAGNAR Investigators. Pant S, et al. Lancet Oncol. 2023 Aug;24(8):925-935. doi: 10.1016/S1470-2045(23)00275-9. Lancet Oncol. 2023. PMID: 37541273 Clinical Trial.
Zanubrutinib: past, present, and future.
Tam CS, Muñoz JL, Seymour JF, Opat S. Tam CS, et al. Blood Cancer J. 2023 Sep 11;13(1):141. doi: 10.1038/s41408-023-00902-x. Blood Cancer J. 2023. PMID: 37696810 Free PMC article. Review.
33,808 results
You have reached the last available page of results. Please see the User Guide for more information.